NCT04607200View on ClinicalTrials.gov

AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma

PHASE2WithdrawnINTERVENTIONAL

0

Timeline

Start Date

February 28, 2021

Primary Completion Date

September 13, 2021

Study Completion Date

September 13, 2021

Conditions

Angiosarcoma

Interventions

DRUG

AGEN2034

Anti-PD-1 Monoclonal Antibody

DRUG

AGEN1884

Anti-CTLA-4 Monoclonal Antibody

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Agenus Inc.

INDUSTRY